Active Share (vs S&P 500): 99.4%
· vs QQQ: 100.0%
— share of the book that differs from index weights (higher = more active)
· ranking
Est. Qtr Return (Q2 2026 → Q3 2026):
-7.2%
· vs SPY
-9.3%
· Prev Value $427.54M
— last quarter positions weighted by this quarter price moves
· ranking
Est. QTD Return (Q3 2026 → newest close):
+6.8%
· vs SPY
+4.6%
· Latest Value $376.70M
— latest reported positions valued at quarter-to-date price moves (still in progress)
· ranking
In its Q3 2026 13F filing, BOONE CAPITAL MANAGEMENT LLC disclosed 16 equity positions with a combined reported value of $376.70M. The filing implies a focused portfolio: its ten largest positions account for 81.1% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2026 were BMRN ($40.32M), TFX ($36.12M), MIRM ($35.53M). By sector, the heaviest allocations are Health Care 75.8%, Consumer Staples 7.8%. Versus the prior quarter, allocation shifted toward Industrials (+7.3pp), Technology (+3.4pp) and away from Consumer Discretionary (-0.8pp), Health Care (-10.8pp).
Versus the prior quarter, BOONE CAPITAL MANAGEMENT LLC opened 5 new positions, trimmed 5 and fully exited 5, a turnover rate of 71.4% of positions. The portfolio's overlap with the prior quarter was 52% of names.
The largest new positions opened in Q3 2026 were AVTR ($27.68M), LH ($26.98M), EHC ($25.01M).
Of the 5 positions fully exited versus the prior quarter, the largest were IONS ($41.23M), GLUE ($14.89M), KOD ($14.73M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
Latest BOONE CAPITAL MANAGEMENT LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Boone Capital Management is an SEC-registered 13F filer based in Atlanta, GA, United States. As of Q3 2026 it reported 16 US equity positions with a combined value of $376.70M. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).
Regulatory AUM (Form ADV): $963.17M as of 2026-03-30
Client mix (by RAUM): pension and profit-sharing plans 100%
Manages 1 private funds, of which 1 hedge funds
Portfolio Structure
16 positions · $376.70M reported value (Q3 2026)
Top 10 holdings = 81.1% of reported value
Largest position: BMRN (BIOMARIN PHARMACEUTICAL INC) at 10.7%
Average position size: $23.54M
Sector Tilt
Health Care 75.8%
Consumer Staples 7.8%
Industrials 7.3%
(classified holdings cover 100% of value)
Quarterly Activity
Q3 2026: 5 new, 3 added, 5 reduced, 5 exited
3 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
AI Rebalance Analysis
1. Overall direction and market view: The fund increased exposure to Health Care (70% of top-10) and added new positions, suggesting a bullish tilt toward biotech/pharma but reduced some existing holdings, indicating selective profit-taking.
2. Key moves:
- Added: BMRN (+2.89% wt), GRDN (+0.88% wt)
- Reduced: TFX (-1.90% wt), CI (-2.17% wt), VSTS (-0.83% wt)
- New: AVTR (7.35% wt), LH (7.16% wt), EHC (6.64% wt)
3. Portfolio structure: Active, concentrated (top-10 = 72.4%), with heavy Health Care bias; moderate risk via biotech (BMRN, MIRM) and defensive staples (GRDN).
4. Per-holding one-liner:
- BMRN: Biopharma (unverified: enzyme therapies)
- TFX: Medical devices (unverified: procedural tools)
- MIRM: Rare-disease biopharma (unverified: liver treatments)
- UNH: Health insurer (unverified: managed care)
- CI: Health insurer (unverified: managed care)
- GRDN: Pharmacy services (unverified: specialty pharmacy)
- AVTR: Lab/industrial chemicals (unverified: life sciences)
- LH: Diagnostics (unverified: lab testing)
- EHC: Post-acute care (unverified: rehab hospitals)
- VSTS: Retail apparel (unverified: workwear)
5. Style summary: Aggressive Health Care focus with new biotech/diagnostics bets and selective trims in non-core positions.
Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 12:05
Every 13F share count is marked to the quarter-end close, rebuilding the NAV this
portfolio would have earned had it done nothing all quarter. This is a historical
reconstruction from already-public filings and prices — not a model forecast, so
precision/recall do not apply.
2023-Q3 = 100. Solid = reconstructed NAV, dashed = SPY benchmark.
Prices are split-adjusted closes and exclude dividends, so dividend-heavy
portfolios would in reality sit slightly above this line.
This portfolio is broadly diversified (Top-10 = 82.6% of reported value), so a
Top-10 proxy cannot represent the whole fund — only the full-holdings reconstruction is shown.
Why there is no forecast NAV
Not published because:
Top-10 covers < 85% of reported value · Holdings-forecast backtest F1 < 0.80 · Top-10 quarterly turnover > 20%
Source: full 13F positions marked to quarter-end closes (computed 2026-11-02 01:13:11).
Share counts and prices are used as a ratio, so splits cancel out.
Holdings Prediction Model
Predicts next-quarter Top-10 holdings and weights from the fund's own historical
trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative
volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through
quarter T. Weights are shares of the modelled portfolio.
The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.
Latest-Quarter Accuracy (2026-Q3)
P 70%R 70%F1 70%(modelled on 2026-Q2; 7/10 hit)
Low-confidence forecast
This fund replaces about 29% of its Top-10 each quarter and
backtests at F1 69% (threshold 80%).
Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.
★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.
Barra Factor Attribution
The disclosed long US equity book from the 2026-Q3 13F is held at its
report-date weights and decomposed over 2026-09-30 ~ 2026-11-16.
The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional
factor returns and an EWMA factor covariance for risk. The “portfolio” is the
visible 13F book, not the fund's true NAV.
The quarter is not complete yet; the window ends at the latest available price date, 2026-11-16, and will update as prices arrive.
Portfolio return+9.54%Buy & hold
QQQ synthetic benchmark-17.01%Liquidity weighted
Excess return+26.55%vs benchmark
Barra annualised vol26.5%Model estimate
Realised vol19.9%Annualised in window
Weighted beta0.64Raw exposure
Factor / specific risk54% / 46%Share of variance
Top-10 concentration100.0%Of reported value
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.
1. Performance
Metric
Value
Note
Portfolio return (buy & hold)
+9.54%
Disclosed long book
QQQ synthetic benchmark
-17.01%
Liquidity-weighted constituents
Model universe, equal weight
-1.70%
Opportunity-cost reference
Excess return
+26.55%
Portfolio − benchmark
Arithmetic return sum
+9.37%
Difference vs compounded is the cross term
Weighted raw beta
0.64
Weighted holding betas
Realised volatility (annualised)
19.87%
Daily returns in window
Barra model volatility (annualised)
26.47%
Factor + specific
Factor share of variance
53.8%
Barra factors
Specific share of variance
46.2%
Stock residuals
Reported value
$135.0M
13F long US equity
2. Return attribution
The +9.37% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.
Factor group
Factors
Contribution
Share of |return|
Size & Liquidity
6
-2.84%
-30.3%
Momentum & Growth
3
-1.19%
-12.7%
Volatility & Tail Risk
7
+5.88%
62.8%
Industry
12
+5.56%
59.3%
Specific
1
+1.97%
21.0%
Factor
Type
Exposure
Factor return
Contribution
Share of |return|
Residual Volatility
Style
+1.39
+3.29%
+4.56%
48.7%
Health Care
Industry
+0.64
+6.98%
+4.46%
47.6%
Historical Volatility
Style
-0.18
-14.00%
+2.52%
26.9%
Specific
Specific
—
—
+1.97%
21.0%
Kurtosis
Style
+0.20
+7.51%
+1.51%
16.1%
Leverage (Downside Vol)
Style
-0.78
-1.71%
+1.33%
14.2%
Size
Style
-0.62
-1.95%
+1.21%
12.9%
Non-linear Size
Style
+1.06
+1.01%
+1.07%
11.5%
Consumer Discretionary
Industry
+0.16
+6.71%
+1.05%
11.2%
Max Drawdown
Style
-0.34
-1.76%
+0.59%
6.3%
Growth
Style
+0.34
+1.75%
+0.59%
6.3%
Liquidity
Style
-0.18
+0.36%
-0.06%
-0.7%
Amihud Illiquidity
Style
+1.06
-0.45%
-0.47%
-5.0%
Beta
Style
-0.23
+4.44%
-1.03%
-11.0%
Momentum
Style
+0.45
-4.00%
-1.80%
-19.2%
Turnover
Style
+0.45
-4.80%
-2.16%
-23.0%
Mid Cap
Style
+1.26
-1.94%
-2.43%
-25.9%
Skewness
Style
+0.82
-4.39%
-3.61%
-38.5%
3. Risk attribution
Annualised volatility is 26.47%; factor risk explains 53.8% of variance and specific risk 46.2%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.
Factor
Type
Exposure
Share of variance
Vol contribution
Share of vol
Specific
Specific
—
46.2%
+12.24%
12.2%
Health Care
Industry
+0.64
19.0%
+5.04%
5.0%
Mid Cap
Style
+1.26
8.4%
+2.23%
2.2%
Industrials
Industry
+0.20
4.6%
+1.23%
1.2%
Leverage (Downside Vol)
Style
-0.78
4.5%
+1.20%
1.2%
Size
Style
-0.62
4.1%
+1.09%
1.1%
Consumer Discretionary
Industry
+0.16
3.9%
+1.03%
1.0%
Momentum
Style
+0.45
3.5%
+0.93%
0.9%
Max Drawdown
Style
-0.34
2.3%
+0.60%
0.6%
Amihud Illiquidity
Style
+1.06
2.0%
+0.54%
0.5%
Residual Volatility
Style
+1.39
1.5%
+0.39%
0.4%
Growth
Style
+0.34
1.4%
+0.38%
0.4%
Turnover
Style
+0.45
0.5%
+0.14%
0.1%
Non-linear Size
Style
+1.06
0.5%
+0.12%
0.1%
Kurtosis
Style
+0.20
0.3%
+0.09%
0.1%
Liquidity
Style
-0.18
0.3%
+0.07%
0.1%
Historical Volatility
Style
-0.18
0.2%
+0.06%
0.1%
Beta
Style
-0.23
-1.6%
-0.44%
-0.4%
Skewness
Style
+0.82
-1.8%
-0.49%
-0.5%
4. Style exposures
Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.
Style factor
Portfolio
QQQ benchmark
Difference
Size
-0.62
+2.10
-2.72
Non-linear Size
+1.06
+1.68
-0.61
Mid Cap
+1.26
+0.13
+1.13
Beta
-0.23
+1.29
-1.53
Momentum
+0.45
+0.72
-0.27
Short-term Reversal
+0.01
-0.64
+0.66
Residual Volatility
+1.39
-0.40
+1.79
Historical Volatility
-0.18
+0.86
-1.04
Liquidity
-0.18
+0.11
-0.29
Amihud Illiquidity
+1.06
+1.16
-0.09
Turnover
+0.45
+0.21
+0.24
Growth
+0.34
+0.58
-0.24
Leverage (Downside Vol)
-0.78
+0.14
-0.92
Skewness
+0.82
+0.24
+0.58
Kurtosis
+0.20
+0.21
-0.01
Max Drawdown
-0.34
-0.08
-0.25
5. Industry allocation & Brinson
Sector
Portfolio
Benchmark
Portfolio ret
Benchmark ret
Allocation
Selection
Interaction
Total
Information Technology
0.0%
73.6%
+0.00%
-22.33%
+3.83%
+16.44%
-16.44%
+16.44%
Health Care
63.8%
1.7%
+13.43%
+8.29%
+15.79%
+0.09%
+3.20%
+8.43%
Communication Services
0.0%
2.6%
+0.00%
-17.64%
+0.01%
+0.46%
-0.46%
+0.46%
Consumer Discretionary
15.7%
8.8%
+2.47%
+3.76%
+1.43%
-0.11%
-0.09%
+0.06%
Utilities
0.0%
0.8%
+0.00%
+11.13%
-0.22%
-0.09%
+0.09%
-0.09%
Industrials
20.5%
11.1%
+1.79%
+4.36%
+2.02%
-0.29%
-0.24%
-0.12%
Consumer Staples
0.0%
0.8%
+0.00%
+15.26%
-0.27%
-0.13%
+0.13%
-0.13%
Total
+22.47%
+16.35%
-13.79%
+25.03%
6. Holdings & contribution
Symbol
Name
Sector
Weight
Return
Contribution
QoQ
UNH
UNITEDHEALTH GROUP INC
Health Care
24.11%
+12.24%
+2.95%
Hold
CI
THE CIGNA GROUP
Health Care
22.60%
+10.42%
+2.35%
Reduce
AVTR
AVANTOR INC
Industrials
20.50%
+1.79%
+0.37%
New
VSTS
VESTIS CORPORATION
Consumer Discretionary
15.67%
+2.47%
+0.39%
Reduce
BBIO
BRIDGEBIO PHARMA INC
Health Care
13.52%
+17.57%
+2.38%
Reduce
MAZE
MAZE THERAPEUTICS INC
Health Care
3.61%
+24.72%
+0.89%
New
Contribution rank
Symbol
Sector
Weight
Return
Contribution
1
UNH
Health Care
24.11%
+12.24%
+2.95%
2
BBIO
Health Care
13.52%
+17.57%
+2.38%
3
CI
Health Care
22.60%
+10.42%
+2.35%
4
MAZE
Health Care
3.61%
+24.72%
+0.89%
5
VSTS
Consumer Discretionary
15.67%
+2.47%
+0.39%
6
AVTR
Industrials
20.50%
+1.79%
+0.37%
7. Conclusions
Over the attribution window 2026-09-30 → 2026-11-16 (33 trading days), the reported portfolio returned +9.54%, versus -17.01% for the QQQ synthetic benchmark — an excess of +26.55%.
Return attribution: the largest positive style/industry contributions came from Residual Volatility +4.56%, Health Care +4.46%, Historical Volatility +2.52%; the largest drags came from Skewness -3.61%, Mid Cap -2.43%, Turnover -2.16%. Specific (stock-level) return contributed +1.97%.
Risk attribution: Barra model volatility is 26.47% annualised; factor risk explains 54% of variance and specific risk 46%. The largest factor risk sources are Health Care 19.0%, Mid Cap 8.4%, Industrials 4.6%.
Style tilt: size -0.62, momentum +0.45, volatility -0.18, liquidity -0.18; the weighted raw beta is 0.64. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
Industry: the largest overweight versus the benchmark is Health Care (+62.1 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +22.47%, selection +16.35% and interaction -13.79%.
Concentration: the top-10 positions are 100.0% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.
FAQ
What did BOONE CAPITAL MANAGEMENT LLC buy in 2026-Q3?
In its 2026-Q3 13F filing, BOONE CAPITAL MANAGEMENT LLC reported 16 equity positions worth $376.70M in aggregate; its largest disclosed positions were BMRN ($40.32M), TFX ($36.12M), MIRM ($35.53M).
How large is BOONE CAPITAL MANAGEMENT LLC's portfolio?
BOONE CAPITAL MANAGEMENT LLC reported $376.70M of long equity holdings across 16 positions as of 2026-Q3. Top-10 holdings account for 81.1% of reported value.
What is BOONE CAPITAL MANAGEMENT LLC's investment style?
HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.
Embed this fund on your site
Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.
<iframe src="https://holdingshub.top/funds/boone-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>